Claims

Search the graph by meaning. Each result carries its current verdict; open one to see its decomposition, provenance, and the reasoning behind the assessment.

1 result

Ezetimibe, a selective intestinal cholesterol absorption inhibitor used as a non-statin lipid-lowering agent, typically as add-on to statins: its LDL-lowering efficacy, safety, and effects on cardiovascular outcomes (e.g., IMPROVE-IT). Not for statin therapy or PCSK9 inhibitors except when directly compared.

Ezetimibe added to statin therapy further lowers LDL cholesterol

UnassessedNo current assessment. Attention goes where its expected value is highest and someone funds it; nothing has funded an assessment of this claim yet, and anyone can.constitution →empirical · derivedA factual claim that rests on inference from other evidence rather than direct observation.constitution →Statin therapy LDL cholesterolimportance · settledImportance 0.15, from 0 to 1 · settled: uncontested, so low even when much depends on it. Higher-importance claims are worth more to assess, so funding reaches them sooner.constitution →

Contribute

If a claim here is wrong, or missing evidence, open it: every claim page carries its own entry for challenges, evidence, and corrections. If the graph is missing a claim or a question entirely, propose it below. A proposal is reviewed on its wording; accepted proposals are matched against the graph before they enter it.